Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.45 |
| ▸ | RPA1 | P27694 | 6/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30492865 | 0.85 | CHRNA7 (0.47) | NR1H4CHRNA7RPA1BCL2L1GPR35 | |
| SCHEMBL25810429 | 0.85 | CHRNA7 (0.47) | NR1H4CHRNA7RPA1BCL2L1GPR35 | |
| SCHEMBL25301143 | 0.84 | CHRNA7 (0.47) | NR1H4CHRNA7RPA1BCL2L1GPR35 | |
| SCHEMBL17858519 | 0.84 | CHRNA7 (0.60) | NR1H4CHRNA7RPA1BCL2L1GPR35 | |
| SCHEMBL31025984 | 0.84 | CHRNA7 (0.60) | NR1H4CHRNA7RPA1BCL2L1GPR35 | |
| SCHEMBL30492882 | 0.83 | CHRNA7 (0.40) | NR1H4CHRNA7L3MBTL1 | |
| SCHEMBL31025963 | 0.83 | SLC16A3 (0.51) | NR1H4RPA1BCL2L1GPR35L3MBTL1 | |
| SCHEMBL17858380 | 0.83 | SLC16A3 (0.51) | NR1H4RPA1BCL2L1GPR35L3MBTL1 | |
| SCHEMBL17858475 | 0.80 | IP6K1 (0.50) | NR1H4CHRNA7RPA1BCL2L1GPR35 | |
| SCHEMBL30492834 | 0.79 | BCL2L1 (0.55) | CHRNA7RPA1BCL2L1GPR35L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074902-A1 | FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR | SHANGHAI JINGXIN BIOMEDICAL CO., LTD. (CN) | 2025-03-06 | — | — | US | disclosed |
| WO-2025002040-A1 | CRYSTAL FORM OR SALT OF BICYCLIC HETEROARYL AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海京新生物医药有限公司 | 2025-01-02 | — | — | WO | disclosed |
| EP-4458824-A1 | FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR | Shanghai Jingxin Biomedical Co., Ltd. (CN) | 2024-11-06 | — | — | EP | disclosed |
| CN-118488951-A | Fused bicyclic heteroaryl amide compounds as inhibitors of protein aggregation | 上海京新生物医药有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2023125376-A1 | FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR | 上海京新生物医药有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023125376-A1 | FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR | 上海京新生物医药有限公司 | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074902-A1 | FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR | HTT, PARK7, FUS | NR1H4 3958/4885CHRNA7 2596/4885RPA1 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.